Description
Regular Meeting
The Cambridge Biosafety Committee meeting meets on a monthly basis so that members may conduct its oversight activities as granted under the Cambridge Recombinant DNA Technology Ordinance (Chapter 8.20) and the Cambridge Biosafety Regulation of 2009.
Link to Agenda (PDF)
AGENDA
Introductions
Statement of purpose for this Special Session of the Cambridge Biosafety Committee
Presentations
1) Committee Oversight of Biosafety Programs at Harvard and MIT (90 mins)
• Review current enforcement challenges within academic biosafety programs
• Discuss strategies to utilize Cambridge Biosafety Committee authority for compliance
• Plan site visits to both institutions to observe best practices and challenges
2) Introductory discussion with Kevin Esvelt and his Rarity research team (30 mins)
• Introduce Rarity research proposal: purpose, stages, challenges
• Review local engagement strategy underway in Martha’s Vineyard/Nantucket
• Consider strategies to engage Cambridge residents to gain public acceptance
Old Business/Site visits
Oct 18 – CRISPR Therapeutics (200 Sidney Street, 3rd Fl) BSL-1/BSL-2 amendment walkthrough
Oct 22 – Sai Life Sciences (400 Technology Square, 2nd Fl) BSL-1/BSL-2 new permit walkthrough
Nov 4 – Directed Genomics (99A Erie Street) BSL-2 ONLY new permit walkthrough
New Business
Nov 15 – LabCentral (700 Main Street) discussion about administrative screening of resident protocols, IBC reviews, IBC reporting expectations to CBC.
Adjourn